Dowsett M - Search Results

1

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.

Garcia-Murillas I, Chopra N, Comino-Méndez I, Beaney M, Tovey H, Cutts RJ, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh-Crestani G, Barry P, Johnston SRD, Ring A, Bliss J, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith IE, Turner NC. Garcia-Murillas I, et al. Among authors: dowsett m. JAMA Oncol. 2019 Oct 1;5(10):1473-1478. doi: 10.1001/jamaoncol.2019.1838. JAMA Oncol. 2019. PMID: 31369045 Free PMC article.

2

Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.

Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M. Chan CM, et al. Among authors: dowsett m. J Steroid Biochem Mol Biol. 2002 Aug;81(4-5):333-41. doi: 10.1016/s0960-0760(02)00074-2. J Steroid Biochem Mol Biol. 2002. PMID: 12361723

3

Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M. Johnston SR, et al. Among authors: dowsett m. Clin Cancer Res. 2003 Jan;9(1 Pt 2):524S-32S. Clin Cancer Res. 2003. PMID: 12538510 Review.

4

Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications.

Ring A, Dowsett M. Ring A, et al. Among authors: dowsett m. Clin Breast Cancer. 2003 Apr;4 Suppl 1:S34-41. doi: 10.3816/cbc.2003.s.013. Clin Breast Cancer. 2003. PMID: 12756077 Review.

5

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.

Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Martin LA, et al. Among authors: dowsett m. J Biol Chem. 2003 Aug 15;278(33):30458-68. doi: 10.1074/jbc.M305226200. Epub 2003 May 29. J Biol Chem. 2003. PMID: 12775708 Free article.

6

Aromatase inhibitors in breast cancer.

Smith IE, Dowsett M. Smith IE, et al. Among authors: dowsett m. N Engl J Med. 2003 Jun 12;348(24):2431-42. doi: 10.1056/NEJMra023246. N Engl J Med. 2003. PMID: 12802030 Review. No abstract available.

7

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.

Johnston SR, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, Salter J, Michiels B, Perez-Ruixo JJ, Palmer P, Howes A. Johnston SR, et al. Among authors: dowsett m. J Clin Oncol. 2003 Jul 1;21(13):2492-9. doi: 10.1200/JCO.2003.10.064. J Clin Oncol. 2003. PMID: 12829668 Clinical Trial.

8

Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells.

Zabaglo L, Ormerod MG, Parton M, Ring A, Smith IE, Dowsett M. Zabaglo L, et al. Among authors: dowsett m. Cytometry A. 2003 Oct;55(2):102-8. doi: 10.1002/cyto.a.10071. Cytometry A. 2003. PMID: 14505315 Free article.

9

Circulating tumour cells in breast cancer.

Ring A, Smith IE, Dowsett M. Ring A, et al. Among authors: dowsett m. Lancet Oncol. 2004 Feb;5(2):79-88. doi: 10.1016/S1470-2045(04)01381-6. Lancet Oncol. 2004. PMID: 14761811 Review.

10

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G, Smith IE. Dowsett M, et al. J Clin Oncol. 2005 Apr 10;23(11):2477-92. doi: 10.1200/JCO.2005.07.559. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767642 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

738 results

Search Page